메뉴 건너뛰기




Volumn 35, Issue 9, 2007, Pages 1358-1365

Cloning and characterization of a human BCR/ABL-positive cell line, K562/RR, resistant to the farnesyltransferase inhibition by tipifarnib

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BETA GLOBIN; CASPASE 3; CASPASE 7; CASPASE 9; CAVEOLIN 2; COMPLEMENTARY DNA; CYCLOOXYGENASE 2; FARNESYLTRANSFERASE ALPHA; FARNESYLTRANSFERASE BETA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NUCLEIC ACID BINDING PROTEIN; PROTEIN CUGBP2; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN FEN1; TIPIFARNIB; UNCLASSIFIED DRUG;

EID: 34548140545     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.05.020     Document Type: Article
Times cited : (4)

References (28)
  • 1
    • 0032704708 scopus 로고    scopus 로고
    • Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development
    • Rowinsky E.K., Windle J.J., and Von Hoff D.D. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol 17 (1999) 3631-3652
    • (1999) J Clin Oncol , vol.17 , pp. 3631-3652
    • Rowinsky, E.K.1    Windle, J.J.2    Von Hoff, D.D.3
  • 2
    • 0033778340 scopus 로고    scopus 로고
    • Farnesyltransferase inhibitors: Novel anticancer mechanisms and new therapeutic applications
    • Gibbs R.A. Farnesyltransferase inhibitors: Novel anticancer mechanisms and new therapeutic applications. Curr Opin Drug Dis Dev 3 (2000) 585-596
    • (2000) Curr Opin Drug Dis Dev , vol.3 , pp. 585-596
    • Gibbs, R.A.1
  • 3
    • 0034730625 scopus 로고    scopus 로고
    • Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules
    • Ashar H.R., James L., Gray K., et al. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem 275 (2000) 30451-30457
    • (2000) J Biol Chem , vol.275 , pp. 30451-30457
    • Ashar, H.R.1    James, L.2    Gray, K.3
  • 4
    • 0032541625 scopus 로고    scopus 로고
    • Non-Ras targets of farnesyltransferase inhibitors: focus on Rho
    • Lebowitz P.F., and Prendergast G.C. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene 17 (1998) 1439-1445
    • (1998) Oncogene , vol.17 , pp. 1439-1445
    • Lebowitz, P.F.1    Prendergast, G.C.2
  • 5
    • 17144361932 scopus 로고    scopus 로고
    • Farnesyltransferase inhibitor therapy in acute myelogenous leukemia
    • Gotlib J. Farnesyltransferase inhibitor therapy in acute myelogenous leukemia. Curr Hematol Rep 4 (2005) 77-84
    • (2005) Curr Hematol Rep , vol.4 , pp. 77-84
    • Gotlib, J.1
  • 6
    • 0036738122 scopus 로고    scopus 로고
    • Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells
    • Le Gouill S., Pellat-Deceunynck C., Harousseau J.L., et al. Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells. Leukemia 16 (2002) 1664-1667
    • (2002) Leukemia , vol.16 , pp. 1664-1667
    • Le Gouill, S.1    Pellat-Deceunynck, C.2    Harousseau, J.L.3
  • 7
    • 23844505374 scopus 로고    scopus 로고
    • Farnesyltransferase inhibitors in myelodysplastic syndrome
    • Feldman E.J. Farnesyltransferase inhibitors in myelodysplastic syndrome. Curr Hematol Rep 4 (2005) 186-190
    • (2005) Curr Hematol Rep , vol.4 , pp. 186-190
    • Feldman, E.J.1
  • 8
    • 0035383789 scopus 로고    scopus 로고
    • Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial
    • Karp J.E., Lancet J.E., Kaufmann S.H., et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 97 (2001) 3361-3369
    • (2001) Blood , vol.97 , pp. 3361-3369
    • Karp, J.E.1    Lancet, J.E.2    Kaufmann, S.H.3
  • 9
    • 0037372488 scopus 로고    scopus 로고
    • Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies
    • Cortes J., Albitar M., Thomas D., et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 101 (2003) 1692-1697
    • (2003) Blood , vol.101 , pp. 1692-1697
    • Cortes, J.1    Albitar, M.2    Thomas, D.3
  • 10
    • 11144358447 scopus 로고    scopus 로고
    • Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma
    • Alsina M., Fonseca R., Wilson E.F., et al. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 103 (2004) 3271-3277
    • (2004) Blood , vol.103 , pp. 3271-3277
    • Alsina, M.1    Fonseca, R.2    Wilson, E.F.3
  • 11
    • 0033578751 scopus 로고    scopus 로고
    • A mutant form of human protein farnesyltransferase exhibits increased resistance to farnesyltransferase inhibitors
    • Del Villar K., Urano J., Guo L., and Tamanoi F. A mutant form of human protein farnesyltransferase exhibits increased resistance to farnesyltransferase inhibitors. J Biol Chem 274 (1999) 27010-27017
    • (1999) J Biol Chem , vol.274 , pp. 27010-27017
    • Del Villar, K.1    Urano, J.2    Guo, L.3    Tamanoi, F.4
  • 12
    • 23744461504 scopus 로고    scopus 로고
    • Resistance to farnesyltransferase inhibitors in Bcr/Abl-positive lymphoblastic leukemia by increased expression of a novel ABC transporter homolog ATP11a
    • Zhang B., Groffen J., and Heisterkamp N. Resistance to farnesyltransferase inhibitors in Bcr/Abl-positive lymphoblastic leukemia by increased expression of a novel ABC transporter homolog ATP11a. Blood 106 (2005) 1355-1361
    • (2005) Blood , vol.106 , pp. 1355-1361
    • Zhang, B.1    Groffen, J.2    Heisterkamp, N.3
  • 13
    • 23044465584 scopus 로고    scopus 로고
    • Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide (SCH66336)
    • Bruzek L.M., Poynter J.N., Kaufmann S.H., and Adjei A.A. Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide (SCH66336). Mol Pharmacol 68 (2005) 477-486
    • (2005) Mol Pharmacol , vol.68 , pp. 477-486
    • Bruzek, L.M.1    Poynter, J.N.2    Kaufmann, S.H.3    Adjei, A.A.4
  • 14
    • 0036284741 scopus 로고    scopus 로고
    • Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line
    • Smith V., Rowlands M.G., Barrie E., Workman P., and Kelland L.R. Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line. Clin Cancer Res 8 (2002) 2002-2009
    • (2002) Clin Cancer Res , vol.8 , pp. 2002-2009
    • Smith, V.1    Rowlands, M.G.2    Barrie, E.3    Workman, P.4    Kelland, L.R.5
  • 15
    • 23844540638 scopus 로고    scopus 로고
    • Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341
    • Buzzeo R., Enkemann S., Nimmanapalli R., et al. Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341. Clin Cancer Res 11 (2005) 6057-6064
    • (2005) Clin Cancer Res , vol.11 , pp. 6057-6064
    • Buzzeo, R.1    Enkemann, S.2    Nimmanapalli, R.3
  • 16
    • 0025808242 scopus 로고
    • Functional activity of myogenic HLH proteins requires hetero-oligomerization with E12/E47-like proteins in vivo
    • Lassar A.B., Davis R.L., Wright W.E., et al. Functional activity of myogenic HLH proteins requires hetero-oligomerization with E12/E47-like proteins in vivo. Cell 66 (1991) 305-315
    • (1991) Cell , vol.66 , pp. 305-315
    • Lassar, A.B.1    Davis, R.L.2    Wright, W.E.3
  • 17
    • 0031002833 scopus 로고    scopus 로고
    • 5-Aminolevulinate synthase expression and hemoglobin synthesis in a human myelogenous leukemia cell line
    • Nagai T., Harigae H., Furuyama K., et al. 5-Aminolevulinate synthase expression and hemoglobin synthesis in a human myelogenous leukemia cell line. J Biochem 121 (1997) 487-495
    • (1997) J Biochem , vol.121 , pp. 487-495
    • Nagai, T.1    Harigae, H.2    Furuyama, K.3
  • 18
    • 0023277545 scopus 로고
    • Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
    • Chomczynski P., and Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162 (1987) 156-159
    • (1987) Anal Biochem , vol.162 , pp. 156-159
    • Chomczynski, P.1    Sacchi, N.2
  • 19
    • 19344369441 scopus 로고    scopus 로고
    • Relative importance of apoptosis and cell cycle blockage in the synergistic effect of combined R115777 and imatinib treatment in BCR/ABL-positive cell lines
    • Miyoshi T., Nagai T., Ohmine K., et al. Relative importance of apoptosis and cell cycle blockage in the synergistic effect of combined R115777 and imatinib treatment in BCR/ABL-positive cell lines. Biochem Pharmacol 69 (2005) 1585-1594
    • (2005) Biochem Pharmacol , vol.69 , pp. 1585-1594
    • Miyoshi, T.1    Nagai, T.2    Ohmine, K.3
  • 20
    • 0034254368 scopus 로고    scopus 로고
    • Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance
    • Mahon F.X., Deininger M.W., Schultheis B., et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96 (2000) 1070-1079
    • (2000) Blood , vol.96 , pp. 1070-1079
    • Mahon, F.X.1    Deininger, M.W.2    Schultheis, B.3
  • 21
    • 0033986790 scopus 로고    scopus 로고
    • The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis
    • Jiang K., Coppola D., Crespo N.C., et al. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol 20 (2000) 139-148
    • (2000) Mol Cell Biol , vol.20 , pp. 139-148
    • Jiang, K.1    Coppola, D.2    Crespo, N.C.3
  • 22
    • 0034777538 scopus 로고    scopus 로고
    • Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells
    • Tamanoi F., Gau C.-L., Jiang C., Edamatsu H., and Kato-Stankiewicz J. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells. Cell Mol Life Sci 58 (2001) 1636-1649
    • (2001) Cell Mol Life Sci , vol.58 , pp. 1636-1649
    • Tamanoi, F.1    Gau, C.-L.2    Jiang, C.3    Edamatsu, H.4    Kato-Stankiewicz, J.5
  • 23
    • 0001686739 scopus 로고    scopus 로고
    • Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
    • Shah N.P., Nicoll J.M., Nagar B., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2 (2002) 117-125
    • (2002) Cancer Cell , vol.2 , pp. 117-125
    • Shah, N.P.1    Nicoll, J.M.2    Nagar, B.3
  • 24
    • 2142647335 scopus 로고    scopus 로고
    • The biology of caveolae: lessons from caveolin knockout mice and implications for human disease
    • Hnasko R., and Lisanti M.P. The biology of caveolae: lessons from caveolin knockout mice and implications for human disease. Mol Interv 3 (2003) 445-464
    • (2003) Mol Interv , vol.3 , pp. 445-464
    • Hnasko, R.1    Lisanti, M.P.2
  • 25
    • 23044449149 scopus 로고    scopus 로고
    • Multiple but dissectible functions of FEN-1 nucleases in nucleic acid processing, genome stability and diseases
    • Shen B., Singh P., Liu R., et al. Multiple but dissectible functions of FEN-1 nucleases in nucleic acid processing, genome stability and diseases. Bioessays 27 (2005) 717-729
    • (2005) Bioessays , vol.27 , pp. 717-729
    • Shen, B.1    Singh, P.2    Liu, R.3
  • 26
    • 0037245474 scopus 로고    scopus 로고
    • Coupled mRNA stabilization and translational silencing of cyclooxygenase-2 by a novel RNA binding protein, CUGBP2
    • Mukhopadhyay D., Houchen C.W., Kennedy S., Dieckgraefe B.K., and Anant S. Coupled mRNA stabilization and translational silencing of cyclooxygenase-2 by a novel RNA binding protein, CUGBP2. Mol Cell 11 (2003) 113-126
    • (2003) Mol Cell , vol.11 , pp. 113-126
    • Mukhopadhyay, D.1    Houchen, C.W.2    Kennedy, S.3    Dieckgraefe, B.K.4    Anant, S.5
  • 27
    • 0034471496 scopus 로고    scopus 로고
    • Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia
    • Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 37 (2000) 431-502
    • (2000) Crit Rev Clin Lab Sci , vol.37 , pp. 431-502
    • Fosslien, E.1
  • 28
    • 33746896137 scopus 로고    scopus 로고
    • Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma
    • Kern M.A., Haugg A.M., Koch A.F., et al. Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res 66 (2006) 7059-7066
    • (2006) Cancer Res , vol.66 , pp. 7059-7066
    • Kern, M.A.1    Haugg, A.M.2    Koch, A.F.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.